Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

CTI to focus on Pixantrone and OPAXIO Approval and Commercialization

SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and Spectrum established a joint venture in December 2008 to develop and commercialize Zevalin. At that time CTI contributed all of the Zevalin related assets to the joint venture and sold to Spectrum a 50% membership interest in the joint venture for $15 million, plus certain milestone payments.

The Company will focus its resources on the approval of pixantrone for relapsed aggressive non-Hodgkin's lymphoma (NHL) and OPAXIO for non-small cell lung and ovarian cancer. CTI estimates that as a result of the sale of the Zevalin interest it will reduce expenses by approximately $15 million annually from activities previously associated with Zevalin while providing CTI with non-dilutive source of operating capital.

"CTI continues to believe in the value of Zevalin as a commercially attractive product and effective form of cancer therapy; however, with the impressive clinical trial results for pixantrone and given the company's need for operating capital, we are compelled to exercise our option and focus our resources on pixantrone," noted James Bianco, MD, CEO of CTI. "CTI has been proud to have provided Zevalin to patients since we acquired it in December, 2007 and having the foresight to bring the first line consolidation for indolent NHL data to the FDA for potential label expansion in the front line consolidation setting. With the progress we made in removing many of the barriers that prevent its more widespread use, we are confident Spectrum will be able to ultimately make Zevalin a commercially attractive product."

At the closing of the sale of CTI's 50% m
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... , July 28, 2014  David Hardison, Ph.D., ... by Deloitte , has been elected chairman of ... Consortium, a non-profit working to establish common protocols ... as it relates to electronic health records. ... mission of collaborating with organizations across the research ...
(Date:7/28/2014)... July 28, 2014 It’s a hard truth: ... benefits to further their post-secondary education are failing to obtain ... released this year. And according to an analysis by ... is veteran students’ uninformed choice of college majors, which leads ... of the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... 28, 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... is a technique used to determine the size of a ... is crucial to analyze the size of particles as it ... analysis is performed to determine the behavior and nature of ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2
... 2012 Oxford BioTherapeutics (OBT) today announces that ... advisor and non-executive director.  Dr Begley, who was the Vice ... Amgen, will take on a key role in helping shape ... its pipeline of oncology antibody-based drugs into clinical development. ...
... Advanstar Communications, is pleased to announce the agenda for ... held April 26 - 27, 2012 at the Loews ... share their strategies for improving patient outcomes and product ... Conference highlights include: , The ...
... Jan. 11, 2012  goBalto, developer of new generation ... completed a FDA 21 CFR Part 11 compliance ... trials application. Tracker,s successful audit will help both ... running clinical trials comply with FDA rules and ...
Cached Biology Technology:Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director 2Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director 3Complete Agenda Announced for 11th Annual Patient Adherence Forum 2goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit 2
(Date:7/28/2014)... Norwegian explorer Roald Amundsen reached the South Pole in ... arrived long before any human. , Using data from ... the Antarctic continent, including the South Pole, a group ... (DRI) in Reno, Nevada, created the most accurate and ... southernmost continent. The new record, described in an article ...
(Date:7/28/2014)... Yale School of Medicine have pinpointed a mechanism in part ... in the blood, linking it to both type 1 and ... 28 issue of Proceedings of the National Academies of ... enzyme located in a part of the hypothalamus known ... in motion that control glucose levels in the blood," said ...
(Date:7/28/2014)... findings of a new study suggest two ways to effectively ... as well in obese women, compared to women of a ... one-size-fits-all method, researchers say, but as the population has increased ... works for obese women. Studies have consistently found that obesity ... which may in turn affect how well the pill prevents ...
Breaking Biology News(10 mins):Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Glucose 'control switch' in the brain key to both types of diabetes 2Strategies identified to improve oral contraceptive success with obese women 2
... developed a clever method to purify parasitic organisms from ... proteomic studies and a deeper insight into the biology ... each year. Many infectious pathogens, like those ... have a complex life cycle alternating between free-living creature ...
... carbon dioxide from burning of fossil fuels might be kept below ... next few decades, say researchers. They say that less plentiful oil ... greater supplies of coal mean that it must be the main ... Biogeochemical Cycles . , ...
... addition to social factors when selecting a mate. In ... PLoS Genetics, scientists in China, France, and the ... be involved in mate choice in some human populations. ... Major Histocompatibility Complex (MHC), a large genomic region involved in ...
Cached Biology News:Curbing coal emissions alone might avert climate danger, say researchers 2Curbing coal emissions alone might avert climate danger, say researchers 3
See product name for description....
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
... Serum • Rhesus serum is collected from ... years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Porcine Serum US Origin 6 Months or Older...
Biology Products: